Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 141.80
Bid: 142.00
Ask: 142.40
Change: 0.80 (0.57%)
Spread: 0.40 (0.282%)
Open: 146.00
High: 146.20
Low: 141.00
Prev. Close: 141.00
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 update

19 Mar 2020 07:00

ELEMENTIS PLC - COVID-19 update

ELEMENTIS PLC - COVID-19 update

PR Newswire

London, March 18

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Elementis plc

COVID-19 update

Suspension of the 2019 final dividend and relaxation of banking covenants

Elementis plc (“Elementis” or the “Group”), a global specialty chemicals company, today provides an update on the impact of the COVID-19 pandemic on its business and a change to its banking covenants.

Business performance

Up to 18 March 2020, the Group has experienced a solid start to the year with limited impact on production and demand from COVID-19. Our sites around the world remain open and are operating at normal levels. Trading and performance has been in line with our expectations, benefitting from efficiency actions implemented in 2019, with overall progress in Personal Care, Coatings and Talc. Market conditions are unchanged in Chromium.

The impact of COVID-19 however presents significant demand and operating uncertainty. Our immediate priorities remain safeguarding the health and wellbeing of our employees, and supporting our customers.

The Group is also taking steps to mitigate any potential material adverse financial impact, with focus on optimisation of cash flow via cost savings, working capital reduction and tight management of capex.

Liquidity, banking covenants and dividend

The Group has very ample liquidity, with in total over $300m immediately available. Total net debt for the Group, excluding lease liabilities under IFRS 16, was $454m at 31 December 2019, representing a ratio of 2.7x EBITDA*.

Elementis is a highly cash generative business, with average operating cash conversion of over 90% over the last 3 years. However, given market and economic uncertainties, the Group has taken two steps to provide additional financial headroom and preserve cash.

First, Elementis has secured a relaxation of its banking covenants from 3.25x to 3.75x net debt/EBITDA*. This will apply for two testing periods (i.e. 30 June 2020 and 31 December 2020).

Second, the Board has decided that given the uncertainties at this time it is prudent to preserve cash. Therefore, the 2019 final dividend of 4.4487 pence per share will no longer be proposed at the AGM scheduled for 29 April 2020. The cash impact of this decision to suspend the dividend is $33m in H1 2020. Future dividend decisions will be made as and when conditions normalise.

Paul Waterman, CEO of Elementis said:

“While our business performance to-date is in line with our expectations, we are acutely aware of the increased level of market and macroeconomic uncertainty. Our focus remains on what we can control, namely active cost and cash management. The relaxation of our banking covenants and the decision to suspend the final dividend will create material additional financial headroom to counter the potential impacts of the global COVID-19 crisis.”

Enquiries

Elementis plcJames Curran, Investor Relations Tel: 020 7067 2994

Tulchan Martin Robinson Tel: 020 7353 4200David Allchurch

Note: *Pre IFRS 16

Date   Source Headline
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021
1st Mar 20222:03 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.